The treatment landscape for bladder cancer has evolved significantly in recent years, leading to improved outcomes.
In this webcast, Dr. Thomas Powles, Chair of Barts Cancer Centre (UK), joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on Antibody Drug Conjugates (ADCs) and other innovative therapies developed for metastatic bladder cancer.
Key topics discussed in this webcast:
Dr. Thomas Powles
Dr. Powles is a renowned expert in urology cancer and drug development, serving as the Chair of the Barts Cancer Centre at St. Bartholomew’s Hospital, Queen Mary University of London. He leads numerous clinical trials across all phases. Notably, his work in bladder and renal cancer has been pivotal in establishing new immunotherapy and antibody drug conjugate treatments as standards of care globally. Dr. Powles has been included in TIME’s list of the 100 most influential people in global health and in the Nature10 list in 2023.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
Our new Webcast series features in-depth conversations with thought leaders in precision therapeutics. Join our speakers as they engage in insightful fireside chat-style discussions on a variety of topics in this dynamic space.
Subscribe to our newsletter to not miss our future Webcasts!